No Data
No Data
Haite Biotech (300683.SZ): As of May 20, the number of shareholders of the company was 12,790
Gelonghui, May 23丨Haite Biotech (300683.SZ) said on the investor interactive platform that as of May 20, the number of shareholders of the company was 12,790.
Haite Biotech (300683.SZ): Commercial sales of the new injectable epneamin have begun
Glonghui, May 23丨Haite Biotech (300683.SZ) said on the investor interactive platform that commercial sales of the company's new injectable epneamin have begun, and the company will actively promote the marketing of this product to bring new profit growth points to the company.
Haite Biotech (300683.SZ): Commercial sales of the product CPT have recently begun
Gelonghui, May 9丨Haite Biotech (300683.SZ) said on the investor interactive platform that the company's product CPT has recently begun commercial sales.
Haite Biotech (300683.SZ): Recently received a total of 15 million yuan in government grants
Gelonghui, May 7 | Haite Biotech (300683.SZ) announced that the company recently received a total of RMB 15 million in government grants related to revenue.
Haite Biotech (300683.SZ) announced first-quarter results with a net loss of 165.455 million yuan, an increase of 1024%
Haite Biotech (300683.SZ) released its report for the first quarter of 2024. The company's revenue was 1.32...
Haite Biotech (300683.SZ): Subsidiary HKG-320 Injection Obtains Drug Clinical Trial Approval Notice
Gelonghui, April 11丨Haite Biotech (300683.SZ) announced that its subsidiary, Wuhan Haite Biotech Innovative Pharmaceutical Research Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for HKG-320 injection approved and issued by the State Drug Administration. HKG-320 injection is a potassium-channel acid blocker (P-CAB) that can reversibly inhibit the acidification function of proton pumps by combining with potassium ions competitive proton pumps (resting pumps and active pumps). Clinical application
No Data